Pharmacyclics Incorporated Stock Upgraded (PCYC)
NEW YORK (
)
(Nasdaq:
) has been upgraded by TheStreet Ratings from sell to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
Highlights from the ratings report include:
- PCYC's very impressive revenue growth greatly exceeded the industry average of 3.3%. Since the same quarter one year prior, revenues leaped by 2658.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
- PCYC has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 850.1% when compared to the same quarter one year prior, rising from -$7.50 million to $56.25 million.
- The gross profit margin for PHARMACYCLICS INC is currently very high, coming in at 79.40%. It has increased significantly from the same period last year. Along with this, the net profit margin of 72.20% significantly outperformed against the industry average.
- Powered by its strong earnings growth of 700.00% and other important driving factors, this stock has surged by 288.19% over the past year, outperforming the rise in the S&P 500 Index during the same period. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
.
Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics has a market cap of $1.25 billion and is part of the
sector and
industry. Shares are up 33.6% year to date as of the close of trading on Friday.
You can view the full
or get investment ideas from our
.
-- Written by a member of TheStreet RatingsStaff
null
